<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23451" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Indinavir (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pollak</surname>
            <given-names>Eliyah B.</given-names>
          </name>
          <aff>Nova Southeastern University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eliyah Pollak declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23451.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Indinavir is an alpha-amino acid amide protease inhibitor used as a treatment therapy for Human immunodeficiency virus (HIV) infections, which can lead to acquired immunodeficiency syndrome (AIDS). The FDA approved indinavir in 1996 as it was among the first HIV protease inhibitors authorized in the United States.<xref ref-type="bibr" rid="article-23451.r1">[1]</xref>&#x000a0;Indinavir has decreased the likelihood of death due to AIDS progression.&#x000a0; It is no longer available in the United States or Europe as it has many adverse effects, and there are better drugs. The article remains for historical value.</p>
        <p>According to guidelines from the U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, the use of indinavir is no longer recommended. However, it is used off-label as a part of boosted regimen in combination(ritonavir+indinavir). Indinavir is commonly combined with HIV antiretroviral medications, such as the HIV protease inhibitor ritonavir. Indinavir is also subject to a high viral protease gene mutation rate. Therefore an Indinavir monotherapy regime is rarely used to prevent the likelihood of drug resistance.<xref ref-type="bibr" rid="article-23451.r2">[2]</xref></p>
        <p>Recent studies have analyzed the effects of indinavir as an anti-cancer agent.<xref ref-type="bibr" rid="article-23451.r3">[3]</xref>&#x000a0;Human papillomavirus is induced by increased expression of eukaryotic translation initiation factor 4E (eIF4E), potentially leading to cervical cancer. Indinavir is an inhibitor of eIF4E. Therefore, recent research has examined its role as a possible cervical cancer treatment.<xref ref-type="bibr" rid="article-23451.r4">[4]</xref>&#x000a0;According to a recent preclinical study, ritonavir's boosted indinavir regimen decreased tumor hypoxia and improved the delivery of chemotherapeutic drugs. Tissue inhibitor of metalloproteinase-3 (TIMP-3) plays a vital role in carcinogenesis. The study observed that modulation of TIMP-3 by protease inhibitors boosted regimens block the cervical intraepithelial neoplasia(CIN) and carcinoma cervix progression. These observations may lead to new therapeutic indications of protease inhibitors to treat cervical carcinoma; however, substantial research is needed before clinical approval.<xref ref-type="bibr" rid="article-23451.r5">[5]</xref></p>
      </sec>
      <sec id="article-23451.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Indinavir acts through a competitive inhibition mechanism. The medication binds the active catalytic site of HIV protease, inhibiting the enzyme's ability to cleave polypeptides into active, infectious proteins. This inhibition, in turn, decreases the number of cleaved polypeptides in the blood, which therefore aids in reducing the amount of active HIV RNA in vivo.</p>
        <p><bold>Mechanism of Resistance:&#x000a0;</bold>Viral resistance to indinavir is due to mutations that result in the expressing amino acid substitutions in the viral protease and flap mutations.<xref ref-type="bibr" rid="article-23451.r6">[6]</xref>&#x000a0;Additionally, Gag mutations are responsible for resistance to indinavir therapy.<xref ref-type="bibr" rid="article-23451.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Indinavir is rapidly absorbed in the fasting state, and food alters the bioavailability of indinavir. When indinavir is administered with a meal high in calories, fat, and protein, it substantially decreases absorption. However, administering indinavir with light meals does not alter trough concentration and absorption.<bold>Distribution:&#x000a0;</bold>Plasma protein binding of indinavir is approximately 60%.<bold>Metabolism:&#x000a0;</bold>CYP3A4 is the primary enzyme that metabolizes indinavir. Indinavir is metabolized to one glucuronide conjugate and six oxidative metabolites.<bold>Elimination:&#x000a0;</bold>Less than 20% of indinavir is excreted unchanged in the urine. Indinavir has a half-life of 1.8 &#x000b1; 0.4 hours.</p>
      </sec>
      <sec id="article-23451.s3" sec-type="Administration">
        <title>Administration</title>
        <p>Indinavir is&#x000a0;administered orally in 100 mg, 200 mg, 333 mg, and 400 mg capsules. The most common indinavir dosage is 800 mg, which is taken as two 400 mg capsules every 8 hours. Recommendations are that patients do not take the medication with food, only water or other liquids (i.e., tea, juice, or coffee). Patients may choose to take indinavir either 1 hour before a meal or two hours after consuming a meal to maximize absorption. If taken with a large meal rich in protein and/or fat, it will diminish the drug's efficacy&#x000a0;because of reduced absorption.<xref ref-type="bibr" rid="article-23451.r1">[1]</xref>&#x000a0;However, foods such as bread and milk may be consumed with indinavir as long as the portions remain small. If a patient misses a dose, the recommendation is that the patients take the next dose at the appropriate time interval. Therefore, one should not take multiple doses at the same time.</p>
        <p>
<bold>Dual Combination Therapy with Protease Inhibitors (PI)</bold>
</p>
        <p>The following are protease inhibitors used in combination with indinavir. Only one PI would typically be administered concurrently with indinavir. The most common regiment for dual therapy is as follows:</p>
        <p>Indinavir&#x000a0;(800 mg, orally, every 8 hours) + ritonavir<bold>&#x000a0;</bold>(100 mg&#x000a0;to 200 mg, orally twice daily). Note: take ritonavir with 48 oz of water.<xref ref-type="bibr" rid="article-23451.r8">[8]</xref></p>
        <p>
<bold>Combination Therapy with two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</bold>
</p>
        <p>Indinavir (800 mg, orally, every 8 hours) + zidovudine (200 mg, orally, every 8 hours) + lamivudine (150 mg, orally, twice a day)&#x000a0;reduces HIV RNA levels below 500 copies per milliliter.<xref ref-type="bibr" rid="article-23451.r9">[9]</xref></p>
        <p>Studies suggest that both treatment plans result in similar plasma HIV RNA and CD4+ levels.<xref ref-type="bibr" rid="article-23451.r10">[10]</xref></p>
        <p>Optimal dosing remains undetermined for pediatric patients. However, indinavir was considered a category C medication under the prior FDA categorization for drugs in pregnancy.</p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Hepatic impairment:&#x000a0;</bold>If a patient is diagnosed with hepatic insufficiency before starting treatment, the prescriber should lower the indinavir dosage to 600 mg.</p>
        <p><bold>Patients with Renal Impairment: </bold>The pharmacokinetics of indinavir&#x000a0;have&#x000a0;not been&#x000a0;evaluated in patients with renal insufficiency. Furthermore, patients should consume an average of 1.5 liters or approximately six glasses of 8 fluid ounces of liquid daily to ensure adequate hydration. Remaining hydrated will help prevent and severity both nephrolithiasis and/or urolithiasis. Additionally, if nephrolithiasis or urolithiasis occurs, the medication should be held for 24 to 72 hours or discontinued altogether.<xref ref-type="bibr" rid="article-23451.r11">[11]</xref></p>
        <p><bold>Pregnancy Considerations:</bold>&#x000a0;Optimal dosing remains undetermined for pregnant patients. However, indinavir was considered a category C medication under the prior FDA categorization for drugs in pregnancy. According to the manufacturer's product labeling, there is a lack of adequate studies on pregnant patients. Given the inadequate information on the use of&#x000a0;indinavir during pregnancy,&#x000a0;its use is not recommended in HIV-infected pregnant patients. Clinicians should encourage patients exposed to indinavir during pregnancy to register in the antiretroviral pregnancy registry.<xref ref-type="bibr" rid="article-23451.r12">[12]</xref></p>
        <p><bold>Breastfeeding Considerations: </bold>Information regarding the evidence of indinavir use during breastfeeding is limited. Indinavir is not a recommended antiretroviral medication during breastfeeding.<xref ref-type="bibr" rid="article-23451.r13">[13]</xref></p>
      </sec>
      <sec id="article-23451.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Most Common Adverse Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nephrolithiasis/urolithiasis: This may occur with symptoms such as flank pain and hematuria or asymptomatic. Administration of antiretroviral therapy (ART) to patients increases the risk of renal insufficiency.<xref ref-type="bibr" rid="article-23451.r14">[14]</xref>&#x000a0;Indinavir is commonly known for causing lithiasis, specifically nephrolithiasis and ureterolithiasis.<xref ref-type="bibr" rid="article-23451.r1">[1]</xref><xref ref-type="bibr" rid="article-23451.r15">[15]</xref>&#x000a0;This effect is because indinavir is only soluble in acidic conditions.<xref ref-type="bibr" rid="article-23451.r16">[16]</xref>&#x000a0;Additionally, asymptomatic crystalluria has a 66% incidence.<xref ref-type="bibr" rid="article-23451.r17">[17]</xref>&#x000a0;Hepatitis B and hepatitis C comorbidities, inadequate hydration, predisposing kidney conditions, and immune deficiencies increase the risk of nephrolithiasis and renal impairment.<xref ref-type="bibr" rid="article-23451.r1">[1]</xref><xref ref-type="bibr" rid="article-23451.r17">[17]</xref>&#x000a0;Indinavir may also lead to&#x000a0;pyelonephritis. Management of indinavir-associated nephrolithiasis is conservative. Recommendations are to temporarily discontinue the indinavir and maintain adequate hydration with&#x000a0;pain management.</p>
          </list-item>
          <list-item>
            <p>Hyperglycemia, leading to insulin resistance</p>
          </list-item>
          <list-item>
            <p>Heart attack</p>
          </list-item>
          <list-item>
            <p>Diabetes leading to ketoacidosis</p>
          </list-item>
          <list-item>
            <p>Hemolytic anemia</p>
          </list-item>
          <list-item>
            <p>Lipodystrophy</p>
          </list-item>
        </list>
        <p>
<bold>Most Common Less Serve Side Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
        </list>
        <p>
<bold>Rare Side Effect</bold>
</p>
        <p>Hydronephrosis</p>
        <p><bold>Hepatotoxicity: </bold>Likelihood score: C (a frequent cause of serum bilirubin elevations and probable cause of rare instances of clinically apparent liver injury). The pattern of serum enzyme elevations due to indinavir therapy can be cholestatic or hepatocellular, associated with indirect hyperbilirubinemia. Acute liver injury due to indinavir is generally self-limited, although rare cases of acute liver failure have been reported.<xref ref-type="bibr" rid="article-23451.r18">[18]</xref></p>
        <p><bold>Drug Interactions:&#x000a0;</bold>Indinavir is an inhibitor of CYP3A4. Therefore, concurrent administration of indinavir and medications metabolized by CYP3A4 can increase plasma concentrations, increasing therapeutic and adverse effects.&#x000a0;On the contrary, coadministration of indinavir and other medications that inhibit CYP3A4 may reduce indinavir clearance and result in increased plasma concentrations of indinavir. This&#x000a0;interaction commonly occurs with herbal supplements such as St. John's wort (<italic toggle="yes">Hypericum perforatum</italic>) and primarily occurs due to the activation of pregnane-X-receptor (PXR).<xref ref-type="bibr" rid="article-23451.r19">[19]</xref><xref ref-type="bibr" rid="article-23451.r20">[20]</xref></p>
      </sec>
      <sec id="article-23451.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Indinavir metabolism occurs via hepatic cytochrome CYP450, specifically the subfamily CYP3A4;&#x000a0;hence medications metabolized by CYP3A4 are contraindicated.<xref ref-type="bibr" rid="article-23451.r17">[17]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Alpha 1-adrenoreceptor antagonists</p>
          </list-item>
          <list-item>
            <p>Antiarrhythmics</p>
          </list-item>
          <list-item>
            <p>Ergot derivatives</p>
          </list-item>
          <list-item>
            <p>Sedatives and hypnotics</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal motility agents</p>
          </list-item>
          <list-item>
            <p>Neuroleptics</p>
          </list-item>
          <list-item>
            <p>HMG-CoA reductase inhibitors</p>
          </list-item>
          <list-item>
            <p>PDE5 inhibitors</p>
          </list-item>
          <list-item>
            <p>Midazolam<xref ref-type="bibr" rid="article-23451.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Additionally, patients taking phosphodiesterase inhibitors type 5 (PDE5) to treat erectile dysfunction such as sildenafil and tadalafil can cause unwanted side effects such as hypotension and prolonged erections. These side effects&#x000a0;may become exacerbated when taken with indinavir. (according to product labeling)</p>
      </sec>
      <sec id="article-23451.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients with a history of kidney stone formation or those at an increased risk of kidney stone development may still be treated with indinavir, although clinicians can consider other alternatives.<xref ref-type="bibr" rid="article-23451.r1">[1]</xref> However, all patients should be closely monitored during the first six months of treatment. Renal function and urinary health require monitoring throughout treatment with indinavir.<xref ref-type="bibr" rid="article-23451.r17">[17]</xref> The majority of stones produced by indinavir are considered radiolucent. Therefore, conventional methods such as CT scans and X-rays of the kidney, ureters, and bladder (KUB) cannot detect such stones. Therefore, monitoring should occur through a urine analysis capable of detecting crystalluria.<xref ref-type="bibr" rid="article-23451.r17">[17]</xref><xref ref-type="bibr" rid="article-23451.r22">[22]</xref>&#x000a0;Clinicians should monitor HIV viral load and CD4 lymphocyte to select appropriate treatment regimens and opportunistic infection prophylaxis.<xref ref-type="bibr" rid="article-23451.r23">[23]</xref></p>
      </sec>
      <sec id="article-23451.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>A 2001 review of Indinavir overdoses (n=79) took into account all reports of indinavir overdose. It defined an acute overdose as a single dose of 2400 mg and a chronic overdose as recurring doses less than or equal to 2400 mg.<xref ref-type="bibr" rid="article-23451.r24">[24]</xref>&#x000a0;The study found that 66% of patients (52/79) experienced an adverse event. It is important to note that the most common reactions for chronic and acute overdoses were gastrointestinal (nausea, vomiting, abdominal pain) and renal-related (nephrolithiasis/flank pain/renal colic pain).</p>
        <p>Common treatment methods for symptomatic Indinavir overdose include hydration (oral or intravenous), diuresis, and activated charcoal to decrease absorption. 87% of patients recovered based on follow-up information provided (n=45).<xref ref-type="bibr" rid="article-23451.r24">[24]</xref>&#x000a0;Additionally, an overdose report suggested that 50 mg of activated charcoal was given orally in combination with IV fluids, and the patient was asymptomatic within 4 hours of treatment.<xref ref-type="bibr" rid="article-23451.r25">[25]</xref></p>
      </sec>
      <sec id="article-23451.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>According to indinavir overdose data, it was determined that 70% (46/66) overdoses were accidental.<xref ref-type="bibr" rid="article-23451.r24">[24]</xref>&#x000a0;Therefore, all interprofessional healthcare team members must communicate clearly to ensure appropriate care coordination.&#x000a0;</p>
        <p>To decrease the likelihood that a patient misinterprets dosing instructions or is unable to read or comprehend them, patients must receive adequate counsel from a pharmacist and/or clinician. Additionally, those responsible for the patient's care should adequately follow up with the patient to ensure that the patient is dosing indinavir correctly, as compliance is essential for effective treatment. Nurses with specialty training in HIV patient care&#x000a0;can educate patients and their families about the importance of compliance and side effects. Since ineffective dosing and administration can lead to therapeutic failure, these&#x000a0;collaborative strategies can significantly improve patient outcomes with indinavir therapy. A study&#x000a0;concluded that&#x000a0;an interprofessional approach using psychosocial training providers, such as social workers, health educators, and community outreach workers, in collaboration with primary care can enhance&#x000a0;&#x000a0;HIV continuum services.<xref ref-type="bibr" rid="article-23451.r26">[26]</xref>[Level 5]</p>
      </sec>
      <sec id="article-23451.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23451&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23451">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23451/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23451">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23451.s10">
        <title>References</title>
        <ref id="article-23451.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <chapter-title>Protease Inhibitors (HIV)</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31644200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Lua</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Haw</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.</article-title>
            <source>BMC Bioinformatics</source>
            <year>2016</year>
            <month>Dec</month>
            <day>22</day>
            <volume>17</volume>
            <issue>Suppl 19</issue>
            <fpage>500</fpage>
            <pub-id pub-id-type="pmid">28155724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ekins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMurtray</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Extracellular binding of indinavir to matrix metalloproteinase-2 and the alpha-7-nicotinic acetylcholine receptor: implications for use in cancer treatment.</article-title>
            <source>Heliyon</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>e02526</fpage>
            <pub-id pub-id-type="pmid">31687607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baksi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Repositioning of anti-viral drugs as therapy for cervical cancer.</article-title>
            <source>Pharmacol Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>983</fpage>
            <page-range>983-9</page-range>
            <pub-id pub-id-type="pmid">27379616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Capano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Picconi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brundu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pisacane</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sapino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palladino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barillari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Monini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bussolino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ensoli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sgadari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giraudo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction.</article-title>
            <source>Mol Cancer Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>2476</fpage>
            <page-range>2476-2489</page-range>
            <pub-id pub-id-type="pmid">33082275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steinbrecher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.</article-title>
            <source>J Chem Inf Model</source>
            <year>2013</year>
            <month>Aug</month>
            <day>26</day>
            <volume>53</volume>
            <issue>8</issue>
            <fpage>2141</fpage>
            <page-range>2141-53</page-range>
            <pub-id pub-id-type="pmid">23834142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gan</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs.</article-title>
            <source>Molecules</source>
            <year>2019</year>
            <month>Sep</month>
            <day>06</day>
            <volume>24</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">31489889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aarnoutse</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Wasmuth</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>de Boo</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hekster</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rockstroh</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.</article-title>
            <source>Antivir Ther</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-14</page-range>
            <pub-id pub-id-type="pmid">14518700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gulick</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mellors</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Havlir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Richman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Valentine</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meibohm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Emini</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Chodakewitz</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.</article-title>
            <source>N Engl J Med</source>
            <year>1997</year>
            <month>Sep</month>
            <day>11</day>
            <volume>337</volume>
            <issue>11</issue>
            <fpage>734</fpage>
            <page-range>734-9</page-range>
            <pub-id pub-id-type="pmid">9287228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Noble</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Indinavir: a review of its use in the management of HIV infection.</article-title>
            <source>Drugs</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>1165</fpage>
            <page-range>1165-203</page-range>
            <pub-id pub-id-type="pmid">10651394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogo</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Lusco</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Najafian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alpers</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>AJKD Atlas of Renal Pathology: Indinavir Nephrotoxicity.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>e3</fpage>
            <pub-id pub-id-type="pmid">28007196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powis</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kacanek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seage</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Van Dyke</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chadwick</surname>
                <given-names>EG</given-names>
              </name>
              <collab>Pediatric HIV/AIDS Cohort Study (PHACS)</collab>
            </person-group>
            <article-title>Antiretroviral Prescribing Practices Among Pregnant Women Living With HIV in the United States, 2008-2017.</article-title>
            <source>JAMA Netw Open</source>
            <year>2019</year>
            <month>Dec</month>
            <day>02</day>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>e1917669</fpage>
            <pub-id pub-id-type="pmid">31851347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Indinavir</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mat&#x00142;osz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pietraszkiewicz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Firl&#x00105;g-Burkacka</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grycner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Horban</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kowalska</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for kidney disease among HIV-1 positive persons in the methadone program.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>342</fpage>
            <page-range>342-348</page-range>
            <pub-id pub-id-type="pmid">30218298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>El Ters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kashani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Crystalglobulin-induced nephropathy.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>525</fpage>
            <page-range>525-9</page-range>
            <pub-id pub-id-type="pmid">25190731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isnard-Bagnis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tourret</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Nephrotoxicity of antiretrovirals other than tenofovir].</article-title>
            <source>Nephrol Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-66</page-range>
            <pub-id pub-id-type="pmid">29500080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Izzedine</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lescure</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>HIV medication-based urolithiasis.</article-title>
            <source>Clin Kidney J</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">25852859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Indinavir</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gouws</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Viljoen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steenekamp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hamman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Herb-Drug Pharmacokinetic Interactions: Transport and Metabolism of Indinavir in the Presence of Selected Herbal Products.</article-title>
            <source>Molecules</source>
            <year>2015</year>
            <month>Dec</month>
            <day>10</day>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>22113</fpage>
            <page-range>22113-27</page-range>
            <pub-id pub-id-type="pmid">26690396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicolussi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drewe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Butterweck</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meyer Zu Schwabedissen</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of St. John's wort drug interactions revisited.</article-title>
            <source>Br J Pharmacol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>177</volume>
            <issue>6</issue>
            <fpage>1212</fpage>
            <page-range>1212-1226</page-range>
            <pub-id pub-id-type="pmid">31742659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Leonowens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-P&#x000e9;rez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Scarlett</surname>
                <given-names>YV</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Paine</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Indinavir Increases Midazolam <italic>N</italic>-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>724</fpage>
            <page-range>724-731</page-range>
            <pub-id pub-id-type="pmid">31028057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hortin</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Detection of indinavir crystals in urine: dependence on method of analysis.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-50</page-range>
            <pub-id pub-id-type="pmid">10656734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>HIV Infection in Adults: Initial Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>407</fpage>
            <page-range>407-416</page-range>
            <pub-id pub-id-type="pmid">33788514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehman</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Beninger</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sharrar</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>A five-year evaluation of reports of overdose with indinavir sulfate.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>449</fpage>
            <page-range>449-57</page-range>
            <pub-id pub-id-type="pmid">14513658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burkhart</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Kemerer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Indinavir overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1998</year>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>747</fpage>
            <pub-id pub-id-type="pmid">9865247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23451.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional collaboration improves linkages to primary care: a longitudinal analysis.</article-title>
            <source>AIDS Care</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>970</fpage>
            <page-range>970-978</page-range>
            <pub-id pub-id-type="pmid">31530005</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
